• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for TRODELVY issued to IMMUNOMEDICS INC

    6/6/22 4:34:38 AM ET
    $IMMU
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $IMMU alert in real time by email
    Biologic License Application (BLA): 761115
    Company: IMMUNOMEDICS INC
    • Email

    Products on BLA 761115

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    TRODELVY SACITUZUMAB GOVITECAN-HZIY 180MG INJECTABLE;INJECTION Prescription None TBD No

    Approval Date(s) and History, Letters, Labels, Reviews for BLA 761115

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    04/22/2020 ORIG-1 Approval N/A Label (PDF)
    Letter (PDF)
    Review
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761115s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/761115Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761115Orig1s000TOC.cfm
    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    06/03/2022 SUPPL-23 Supplement

    Label is not available on this site.

    04/07/2021 SUPPL-13 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s005s013lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/761115Orig1s005, s013ltr.pdf
    04/13/2021 SUPPL-9 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/761115Orig1s009ltr.pdf
    04/07/2021 SUPPL-5 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s005s013lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/761115Orig1s005, s013ltr.pdf

    Labels for BLA 761115

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    04/13/2021 SUPPL-9 Efficacy-New Indication Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s009lbl.pdf
    04/07/2021 SUPPL-13 Efficacy-New Patient Population Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s005s013lbl.pdf
    04/07/2021 SUPPL-5 Efficacy-Accelerated Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s005s013lbl.pdf
    04/22/2020 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761115s000lbl.pdf
    Get the next $IMMU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMMU

    DatePrice TargetRatingAnalyst
    More analyst ratings